BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Blum K, Lott L, Baron D, Smith DE, Badgaiyan RD, Gold MS. Improving naltrexone compliance and outcomes with putative pro- dopamine regulator KB220, compared to treatment as usual. J Syst Integr Neurosci 2020;7. [PMID: 32934823 DOI: 10.15761/JSIN.1000229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Blum K, Dennen CA, Baron D, Thanos PK, Badgaiyan RD. Offering a putative neurobiological "dopamine homeostatic" solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of "precision behavioral management". Ann Transl Med 2022;10:1291. [PMID: 36618806 DOI: 10.21037/atm-2022-67] [Reference Citation Analysis]
2 Blum K, Han D, Bowirrat A, Downs BW, Bagchi D, Thanos PK, Baron D, Braverman ER, Dennen CA, Gupta A, Elman I, Badgaiyan RD, Llanos-Gomez L, Khalsa J, Barh D, McLaughlin T, Gold MS. Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity Index. J Pers Med 2022;12. [PMID: 36579510 DOI: 10.3390/jpm12111772] [Reference Citation Analysis]
3 Blum K, Han D, Gupta A, Baron D, Braverman ER, Dennen CA, Kazmi S, Llanos-gomez L, Badgaiyan RD, Elman I, Thanos PK, Downs BW, Bagchi D, Gondre-lewis MC, Gold MS, Bowirrat A. Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case–Control Subjects. JPM 2022;12:1385. [DOI: 10.3390/jpm12091385] [Reference Citation Analysis]
4 Braverman ER, Dennen CA, Gold MS, Bowirrat A, Gupta A, Baron D, Roy AK, Smith DE, Cadet JL, Blum K. Proposing a “Brain Health Checkup (BHC)” as a Global Potential “Standard of Care” to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of “Dopamine Homeostasis”. IJERPH 2022;19:5480. [DOI: 10.3390/ijerph19095480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ghanem N, Dromgoole D, Hussein A, Jermyn RT. Review of medication-assisted treatment for opioid use disorder. J Osteopath Med 2022. [PMID: 35285220 DOI: 10.1515/jom-2021-0163] [Reference Citation Analysis]
6 Blum K, Bowirrat A, Braverman ER, Baron D, Cadet JL, Kazmi S, Elman I, Thanos PK, Badgaiyan RD, Downs WB, Bagchi D, Llanos-Gomez L, Gold MS. Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions. Int J Environ Res Public Health 2021;18:11529. [PMID: 34770047 DOI: 10.3390/ijerph182111529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Blum K, Kazmi S, Modestino EJ, Downs BW, Bagchi D, Baron D, McLaughlin T, Green R, Jalali R, Thanos PK, Elman I, Badgaiyan RD, Bowirrat A, Gold MS. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration. J Pers Med 2021;11:212. [PMID: 33809702 DOI: 10.3390/jpm11030212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
8 Blum K. Meet Our Editor-in-Chief. CPSP 2021;10:3-3. [DOI: 10.2174/221155601001210125124530] [Reference Citation Analysis]